anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Recently, Enterococcus has been shown to have gastric protective functions, and the mechanisms by which Enterococcus modulates gastric function are still being investigated. Herein, we investigated how Enterococcus faecium (Efm) and E. faecium-derived extracellular vesicles (EVs) (EfmEVs) exert protective effect against ethanol-induced gastric injury by investigating the effect of EfmEVs on gastric mucosal ulcer scoring, histological lesion, mucosal glycoprotein production, acidity, anti-oxidative function, and inflammatory responses in rat. Pretreatment with Efm showed significant reduction of ethanol-induced gastric injury, as evidenced by the lowering of ulcer index, histological lesion, gastric pH, and inflammatory responses and the enhancement of mucosal glycoprotein production and anti-oxidative function. Further functional studies on three bioactive components [inactivated Efm, EfmEVs (EVs), and EV-free supernatants] of the bacterial culture showed that EVs are mostly responsible for the gastroprotective effect. Moreover, EV secretion is beneficial for the gastroprotective effect of Efm. Hence, EVs mediated the protective effect of Efm against ethanol-induced gastric injury by lowering inflammatory responses and enhancing anti-oxidative function and may be a potent anti-inflammatory and anti-oxidative strategy to alleviate hyperinflammatory gastrointestinal tract conditions.IMPORTANCEThis study indicated that Enterococcus faecium provided a protective effect against rat gastric injury, which involved improvement of the mucosal glycoprotein production, anti-oxidative function, and inflammatory responses. Furthermore, we confirmed that three bioactive components (inactivated Efm, extracellular vesicles, and EV-free supernatants) of E. faecium culture also contributed to the gastroprotective effect. Importantly, E. faecium-derived EVs showed an effective impact for the gastroprotective effect.
Local recurrence post-surgery in early-stage triple-negative breast cancer is a major challenge. To control the regrowth of a residual tumor, we have developed an autologous therapeutic hybrid fibrin glue for intra-operative implantation. Using autologous serum proteins as stabilizers, we have optimized high drug-loaded lapatinib-NanoSera (Lap-NS; ∼66% L.C.) and imiquimod-MicroSera (IMQ-MS; ∼92% L.C). Additionally, plasmonic nanosera (PNS) with an ∼67% photothermal conversion efficiency under 980 nm laser irradiation was also developed. While localized monotherapy with either Lap-NS or PNS reduced the tumor regrowth rate, their combination with IMQ-MS amplified the effect of immunogenic cell death with a high level of tumor infiltration by immune cells at the surgical site. The localized combination immunotherapy with a Nano-MicroSera based hybrid fibrin implant showed superior tumor inhibition and survival with significant promise for clinical translation.
To provide a medical office work rationalization system that eradicates fraudulent claims for medical fees while ensuring reliable identity verification.SOLUTION: A medical institution, such as a hospital, prepares a multifunction reception device equipped with a reader for reading a QR code of an insurance card and an individual number card, and a numeric keypad for inputting a password. The multifunction reception device reads the QR code of the insurance card, or the individual number card and the password, to retrieve an individual number. A system is constructed to retrieve an individual image and various medical information such as a medical chart, which are linked to the individual number. At every medical examination, an interviewed patient is imaged (from the front of the patient at 30 to 45 degrees so as to capture a doctor from diagonally behind). The image is displayed on an electronic medical chart. The electronic medical chart is linked to the individual number, and the electronic medical chart is transmitted to a government-owned AI server 13 together with an electronic bill for medical fee. The AI server requests correction if the content is incorrect, or money can be transferred if the content is correct.SELECTED DRAWING: Figure 1
The invention belongs to the technical field of biological medicines, and particularly relates to a targeting inhibitor of hsa_circ_0008821 genes and application thereof. A targeted inhibitor of the hsa_circ_0008821 gene, which inhibitor has the targeting sequence: 5'-CAGATATTAGGACACTGGGGT-3' (SEQ ID No. 1). The application of the targeted inhibitor of the hsa_circ_0008821 gene in preparing medicaments for treating human brain glioblastoma. The invention develops a targeting inhibitor of hsa_circ_0008821 gene by utilizing RNA interference technology, and the targeting inhibitor can be specifically combined with hsa_circ_0008821 gene to silence hsa_circ_0008821 gene, thereby inhibiting proliferation, migration and invasion capacity of glioblastoma cells and achieving the purpose of treating glioblastoma. The targeting inhibitor of hsa_circ_0008821 gene plays an important role in the field of glioblastoma gene therapy, and provides a new targeting therapeutic drug for clinical treatment of glioblastoma.
The invention relates to a nano-polymer micellar drug delivery system for transferring an anti-cancer drug in cells and the preparation method and application thereof. The invention pertains to the fields of biomedical materials and nano-technology. The delivery system includes a nano-polymer micellar carrier and the anti-cancer drug which is enveloped in the nano-polymer micellar carrier, that is, the endogenous biological molecule is modified on the low generation polyamidoamine dendrimer, so as to prepare the nano-polymer micellar drug delivery system. The invention adopts the low generation polyamidoamine dendrimer and can obtain the polymer micellar with the particle size of about 100nm by carrying out simple surface modification to the the low generation polyamidoamine dendrimer. The experiments prove that the micellar has very good drug delivery function in cells for anti-cancer drug. The invention avoids a plurality of synthesis and follow-up purifying works which are needed in the preparation of high generation polyamidoamine dendrimer and replaced with the drug delivery system with simple preparation and small toxicity and side effects in biological bodies. The invention can be used for the treatment of cancers.
BACKGROUND: Circular RNAs (CircRNAs) have been associated with acute lung injury (ALI), but their molecular mechanisms remain unclear.
METHODS: This study developed a rat model of lipopolysaccharide (LPS)-induced ALI and evaluated the modeling effect by hematoxylin and eosin staining, Masson's trichrome staining, lung wet-to-dry weight ratio, terminal deoxynucleotidyl transferase UTP nick end labeling (TUNEL), and enzyme-linked immunosorbent assay (ELISA) detection of inflammatory factors (interleukin-1β, tumor necrosis factor alpha, and interleukin-6). Using lung tissues from a rat model of LPS-induced ALI, we then conducted circRNA sequencing, mRNA sequencing, and bioinformatics analysis to obtain differential circRNA and mRNA expression profiles as well as potential ceRNA networks. Furthermore, we performed quantitative real-time polymerase chain reaction (qRT-PCR) assays to screen for circ-Phkb in ALI rat lung tissues, alveolar macrophages, and LPS-induced NR8383 cells. We conducted induction with or without LPS with circ-Phkb siRNA and overexpression lentivirus in NR8383. Cell Counting Kit-8, C5-Ethynyl-2'-deoxyuridine (Edu), TUNEL, and cytometry were used to identify proliferation and apoptosis, respectively. We detected inflammatory factors using ELISA. Finally, we used Western blot to detect the apoptosis-related proteins and TLR4/MyD88/NF-kB/CCL2 pathway activation.
RESULTS: Our results revealed that both circRNA and mRNA profiles are different from those of the Sham group. We observed a significant circ-Phkb upregulation in NR8383 cells and LPS-exposed rats. Apoptosis and inflammation were greatly reduced when circ-Phkb expression was reduced in NR8383 cells, cell proliferation was increased, and circ-Phkb overexpression was decreased.
CONCLUSIONS: In terms of mechanism, circ-Phkb suppression inhibits CCL2 expression via the TLR4/MyD88/NF-kB pathway in LPS-induced alveolar macrophages.
Subjects are persons with tetraplegia: spinal cord lesion level C3 to T1, AIS levels A and B, ages 18-65 years or subjects are able-bodied controls matched for age and gender. Procedure is exposure to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 1).
The Enhanced Usual Care (EUC) condition will supplement standard practices within the study sites related to chronic pain and OUD education. Participants randomized to the EUC condition will receive a brochure (in-person, via email, or via text message) with a list of chronic pain treatment resources, signs and management of opioid overdose including naloxone, and overdose prevention, and will encouraged to schedule an appointment with a clinical provider if they would like to discuss any current or past symptoms. In addition to receiving the brochure, EUC condition participants will meet with a therapist remotely for approximately 15 minutes for a descriptive overview of the brochure. In this session, the therapist will point out the resources in the brochure and read the helpful tips out loud to the participant. This session will be audio recorded for fidelity.
This invention relates to a liposome medicament, and, more particularly, a liposome medicament with targeting function. The liposome medicament includes a medicament that is encapsulated in a liposome, and the medicament contains an effector molecule or an effector molecule that is combined with a first ligand, and a second ligand that is connected onto the surface of the liposome. The first ligand and/or the second ligand can specifically bind to target tissues or target cells to be treated. Preferably, the first ligand and/or the second ligands are antibodies, such as monoclonal antibodies. This invention also relates to a method of preparation of the liposome medicament and use of the medicament for treatment of diseases especially tumors. This invention further relates to a pharmaceutical composition of the liposome medicament and a pharmaceutically acceptable carrier.
The proposed study is a twelve week, cross-sectional, double blind, randomized controlled trial. The sample population will consist of one-hundred fifty healthy adult volunteers. All participants will be Malaysian women between eighteen and forty-two years of age. Study participants will be recruited by word of mouth and through advertisements placed in hospitals and universities starting in January 2011. Study participants will be randomly assigned to 1 of 3 treatment groups: 1) 1000ug L-MTHF 2) 1000ug folic acid 3) placebo (methyl cellulose). All treatments will be given in capsule form. Blood samples will be collected at baseline, 6 and 12 weeks.

The primary outcome measure is red cell folate. A sample size of 45 subjects per group will allow us to detect a minimum difference of 100 nmol/L red cell folate assuming an alpha 0.05, a beta of 0.8 a SD of 183 nmol/L. Accounting for a 10% attrition rate we will enroll 50 women per group. The study will be analyzed as intent to treat. Baseline characteristics and compliance between treatment groups will be compared using a one-way ANOVA for continuous variables and chi-square analyses for categorical variables. The difference in measurements between the treatment groups at week 12 will be determined by regression analysis, controlling for baseline values.
Quinolones have been shown to cause arthropathy in immature animals. Degeneration of articular cartilage occurred in juvenile dogs given at least 192 mg/kg/day gemifloxacin in a 28-day study (producing about 6 times the systemic exposure at the clinical dose), but not in mature dogs. There was no damage to the articular surfaces of joints in immature rats given repeated doses of up to 800 mg/kg/day.

Some quinolones have been reported to have proconvulsant properties that are potentiated by the concomitant administration of non-steroidal anti-inflammatory drugs (NSAIDs). Gemifloxacin alone had effects in tests of behavior or CNS interaction typically at doses of at least 160 mg/kg. No convulsions occurred in mice given the active metabolite of the NSAID, fenbufen, followed by 80 mg/kg gemifloxacin.

Dogs given 192 mg/kg/day (about 6 times the systemic exposure at the clinical dose) for 28 days, or 24 mg/kg/day (approximately equivalent to the systemic exposure at the clinical dose) for 13 weeks showed reversible increases in plasma ALT activities and local periportal liver changes associated with blockage of small bile ducts by crystals containing gemifloxacin.

Quinolones have been associated with prolongation of the electrocardiographic QT interval in dogs. Gemifloxacin produced no effect on the QT interval in dogs dosed orally to provide about 4 times human therapeutic plasma concentrations at Cmax, and transient prolongation after intravenous administration at more than 4 times human plasma levels at Cmax. Gemifloxacin exhibited weak activity in the cardiac IKr (hERG) channel inhibition assay, having an IC50 of approximately 270 μM.

Gemifloxacin, like many other quinolones, tends to crystallize at the alkaline pH of rodent urine, resulting in a nephropathy in rats that is reversible on drug withdrawal (oral no-effect dose 24 mg/kg/day).

Gemifloxacin was weakly phototoxic to hairless mice given a single 200 mg/kg oral dose and exposed to UVA radiation. However, no evidence of phototoxicity was observed at 100 mg/kg/day dosed orally for 13 weeks in a standard hairless mouse model, using simulated sunlight.
Ophthalmic solutions are provided for use as tear substitutes and contact lens solutions. These solutions contain a cationic polymeric surfactant that has an affinity for the surface of the eye or a contact lens. Also disclosed are ophthalmic solutions containing a combination of the cationic polymeric surfactant and a water soluble anionic polymer which forms a complex in aqueous solution. The complex has an affinity for the surface of the eye or contact lens. In this manner, the present solutions provide improved duration of comfort to the user. The present compositions are also useful as carriers for ophthalmic drugs.
Provided here are engineered immune cells that comprise a constitutively active chimeric cytokine receptor (CACCR) and a B-cell maturation antigen (BCMA) specific chimeric antigen receptor (CAR). Also provided herein are engineered immune cells that comprise one or more nucleic acids e.g. a bicistronic vector such as a viral vector that encode the CACCRs and BCMA CARs and engineered immune cells e.g. engineered autologous or allogeneic T cells that express both CACCRs and BCMA CARs from the nucleic acids. When present on chimeric antigen receptor (CAR)-bearing engineered immune cells, the CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Further provided herein are methods of making and using the engineered immune cells described herein, such as methods of treating a disease or condition by administering at least one appropriate dose of the cells to a patient suffering from the condition.
This arm will include 50 patients who, at baseline ultrasound, have no gallbladder pathology and have no previous cholecystectomy. Those patients will be taking an oral drug (Ursodeoxycholic Acid 250mg) twice daily for a period of six months and undergoing a total of three gallbladder ultrasounds (at 6 months, at 12 months, and at 18 months) to check for gallstones.
Sterile pharmaceutical cisplatin compositions as oil-in water emulsion having low toxicity for parenteral administration are described. The compositions essentially consist of oil-in-water emulsion with cisplatin in oily phase. The process of making these synergistic compositions has been described. Cisplatin is dispersed in oily phase and emulsified with aqueous phase using emulsifier. Edetate (salt or ester of the ethylenediaminetetraacetic acid) specified in the composition is in quantity sufficient to stabilize and prevent discolouration of the product on autoclaving. 38 claims
INTRODUCTION: Systemic inflammatory response syndrome (SIRS) is the main cause of death in burns and is associated with high burn mortality rates. SIRS occurs when burns are in the subacute phase and is affected by several factors, such as host, trauma and management. The research was conducted at the Burn Center of Dr Soetomo General Hospital, Surabaya, Indonesia, using retrospective observational analytic research design. The aim of the study was to assess the correlation of risk factors which include age, extent of burns, cause of burns, inhalation trauma, history of hyperglycaemia, anaemia, hypoalbuminemia and ESBL infection with the incidence of SIRS.
MATERIALS AND METHODS: The study is observational analytic research using a retrospective design and secondary data of all burn patients treated at the Burn Center of Dr Soetomo General Hospital, Surabaya, Indonesia from January 2018 to December 2019.
RESULTS: A total of 163 burn patients were included. Among comorbidities found were inhalation trauma (39.3%), diabetes mellitus (2.5%), anaemia (14.7%), hypoalbuminemia (40.5%) and ESBL infection (1.2%). A total of 11 patients (6.7%) suffered from SIRS. The statistical analysis showed that anaemia (p=0.012), hypoalbuminemia (p=0.030) and the percentage of burns (p=0.001) were significantly correlated to the incidence of SIRS while age, sex, cause of burn injury, inhalation trauma, diabetes mellitus and ESBL infection have no significant correlation with SIRS.
CONCLUSION: Burn surface area is the most influencing factor of SIRS incident. It is important to meticulously monitor patients with extensive burn areas for indications of SIRS. However, the sample size of this study was relatively small, and it used a retrospective approach, so a larger sample size and a prospective or cohort design method were recommended for further study.
This group will receive 4-week personalized behavioral nutrition intervention with digital self-monitoring for diet and blood glucose and diabetes nutrition education. Participants will discuss the personalized nutrition change goals and recommendations based on metabolic profiling for assessing dietary patterns.
Diclofenac, and other NSAIDs, have caused serious gastrointestinal toxicity, such as bleeding, ulceration and perforation of the stomach, small intestine or large intestine. Misoprostol has been shown to reduce the incidence of endoscopically diagnosed NSAID-induced gastric and duodenal ulcers. In a 12-week, randomized, double-blind, dose-response study, misoprostol 200 mcg administered qid, tid or bid, was significantly more effective than placebo in reducing the incidence of gastric ulcer in OA and RA patients using a variety of NSAIDs. The tid regimen was therapeutically equivalent to misoprostol 200 mcg qid with respect to the prevention of gastric ulcers. Misoprostol 200 mcg given bid was less effective than 200 mcg given tid or qid. The incidence of NSAID-induced duodenal ulcer was also significantly reduced with all three regimens of misoprostol compared to placebo (see Table 2). 

Results of a study in 572 patients with osteoarthritis demonstrate that patients receiving diclofenac sodium and misoprostol delayed-release tablets have a lower incidence of endoscopically defined gastric ulcers compared to patients receiving diclofenac sodium (see Table 3).
Inflammation is an important biological response to any tissue injury. The immune system responds to any stimulus, such as irritation, damage, or infection, by releasing pro-inflammatory cytokines. The overproduction of pro-inflammatory cytokines can lead to several diseases, e.g., cardiovascular diseases, joint disorders, cancer, and allergies. Emerging science suggests that whole grains may lower the markers of inflammation. Whole grains are a significant source of dietary fiber and phenolic acids, which have an inverse association with the risk of inflammation. Both cereals and pseudo-cereals are rich in dietary fiber, e.g., arabinoxylan and β-glucan, and phenolic acids, e.g., hydroxycinnamic acids and hydroxybenzoic acids, which are predominantly present in the bran layer. However, the biological mechanisms underlying the widely reported association between whole grain consumption and a lower risk of disease are not fully understood. The modulatory effects of whole grains on inflammation are likely to be influenced by several mechanisms including the effect of dietary fiber and phenolic acids. While some of these effects are direct, others involve the gut microbiota, which transforms important bioactive substances into more beneficial metabolites that modulate the inflammatory signaling pathways. Therefore, the purpose of this review is twofold: first, it discusses whole grain dietary fiber and phenolic acids and highlights their potential; second, it examines the health benefits of these components and their impacts on subclinical inflammation markers, including the role of the gut microbiota. Overall, while there is promising evidence for the anti-inflammatory properties of whole grains, further research is needed to understand their effects fully.
OBJECTIVE: Tracheoesophageal puncture (TEP) is one of the most established methods for voice reacquisition following total laryngectomy. The most difficult complication following TEP is the management of saliva leakage or secretion into the trachea due to TE fistula enlargement. In this study, we devised a new strategy to close TE fistulas and confirmed its safety and effectiveness.
METHODS: Skin incision: If the tracheal mucosa around the voice prosthesis appears intact and normal, an arcuate incision, from 10 to 2 o'clock, is made on the skin 5 mm superior to the edge of the stoma. However, if the surrounding tracheal mucosa is fragile because of leaking, the incision is made on the superior edge of the stoma, with later reconstruction of the posterior tracheal wall. Separation of the trachea and esophagus: If the esophagotracheal spatium appears normal and is easy to dissect, the connective pipes can be found easily. After cutting the pipe, a ligature alone is sufficient for the tracheal side; however, the esophageal wall is closed with Gambee sutures. If the esophagotracheal spatium is compromised and the posterior tracheal wall is fragile (due to saliva leakage), we remove the posterior wall and reconstruct the area using the superior skin flap. We performed our novel method on four patients with intractable conditions; postradiotherapy for laryngeal cancer, total pharyngo-laryngo-esophagectomy (TPLE) with jejunum reconstruction, TPLE with gastric lifting reconstruction, and in a patient who underwent cervicothoracic incisional drainage for descending necrotizing mediastinitis.
RESULTS: None of the cases showed postoperative leakage from the fistula, and oral intake was resumed without difficulty.
CONCLUSION: This study showed that this strategy based on TE fistula conditions is effective even in difficult-to-treat cases.
Methods of monitoring therapeutic efficacy in a subject with MDS are provided. Also provided is a method of identifying a subject with myelodysplastic syndrome (MDS) for treatment with a telomerase inhibitor, and methods of treating MDS. The subject methods can include administering to the subject an effective amount of a telomerase inhibitor and assessing the hTERT expression levels in a biological sample obtained from the subject. In some cases, a 50% or greater reduction in hTERT expression level identifies a subject who has an increased likelihood of benefiting from treatment with the telomerase inhibitor. The subject can be naive to treatment with a HMA, lenalidomide, or both. In some cases, the subject is classified as having low or intermediate-1 IPSS risk MDS and/or MDS relapsed/refractory to Erythropoiesis-Stimulating Agent 
(ESA). In some instances, the telomerase inhibitor is imetelstat sodium.